Cite
HARVARD Citation
Hilley, P. et al. (n.d.). P028 Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease – what is the opportunity cost of improving access to health care?. Journal of Crohn's and colitis. pp. i197-i198. [Online].